

107. A method of detecting sensitivity in a subject to a cat protein allergen, comprising combining a biological sample obtained from the subject with an isolated polypeptide of claim 101.

108. An isolated nucleic acid encoding the polypeptide of claim 101.

109. A nucleic acid according to claim 108, wherein the nucleic acid is in the form of cDNA.

110. An isolated nucleic acid capable of hybridizing under high stringency conditions to the nucleic acid of claim 108.--

## REMARKS

### Amendments to the Specification

Figure 8 has been deleted. Accordingly, the specification has been amended throughout to delete all reference to Figure 8 and the remaining figures have been renumbered.

The specification has been further amended to comply with 37 C.F.R. §1.812 as amended in the parent application, serial number 08/431,184. In particular, Sequence Descriptions have been amended throughout the Sequence Listing (e.g., SEQ ID NOS:1, 2, 4, 5 etc.) to correct the numbering of amino acids. For example, the leader sequences of chains 1 and 2 of the human T cell reactive feline protein shown in Figures 6 and 7 were incorrectly indicated in the Sequence Listing as being part of the mature T cell reactive feline protein (i.e., the amino acid residues comprising the leader sequence were assigned positive numbers in the Sequence Listing rather than negative numbers). In addition, the General Information Section has been amended to reflect the information for the present application. In addition, the molecule type indicated for SEQ ID NO:71 has been corrected from peptide to cDNA. In addition, SEQ ID NOS: 102 and 103 have been

005169-132580

B1  
CONT.

added into the sequence listing. SEQ ID NOS:102 and 103 correspond respectively to the nucleotide and amino acid sequences of peptide YZX, as shown in Figure 30.

Accordingly, because the corrected replacement Sequence Listing submitted herewith contains a total of 103 sequences, the General Information Section of the Sequence Listing has also been corrected to reflect this new total number of sequences.

For the Examiner's convenience replacement pages have been provided for the specification which are identical to the sequence listing of the parent application, serial number 08/431,184. No new matter has been added. The corrections made to the sequence listing are solely numbering, typographical and format corrections.

Further, in accordance with 37 C.F.R. §1.821(c) and (e), Applicants have submitted on even date herewith a computer readable form of the corrected sequence listing (diskette) which is identical in substance to the paper copy of the sequence listing submitted herewith.

#### Amendments to the Claims

All previously pending claims have been canceled in favor of new claims 95-113. Accordingly, claims 95-113 are currently pending in the application. Support for new claims 95-113 can be found in the specification and the claims as originally filed. No new matter has been added.


005160-10229560

**SUMMARY**

In view of the amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicant's Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

  
Jane E. Remillard, Esquire  
Registration No. 38,872  
Attorney for Applicants

28 State Street  
Boston, Ma 02109  
(617) 227-7400

Date: 9/15/00

005160-18223560